Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Chorea as the Initial Manifestation of Antiphospholipid Syndrome
Autoimmune Neurology
P9 - Poster Session 9 (5:30 PM-6:30 PM)
6-020

Autoimmune chorea, including paraneoplastic, post-infectious, and idiopathic etiologies, is one of the leading causes of adult-onset chorea behind Huntington's and vascular diseases.1 In particular, in primary antiphospholipid syndrome (APS) and systemic lupus erythematosus, chorea is the initial manifestation of disease in 0.9 to 2% of cases.1,2

To discuss a rare case of chorea presenting as the initial manifestation of autoimmune disease.

Verbal and written consent were obtained from the patient.

73-year-old female with PMH of ITP, left MCA ischemic stroke, SDH, and DVT on anticoagulation who presented initially to ED with choreoathetoid movements starting 3 days prior to admission. History was unremarkable for triggering factor. Head imaging was unremarkable for acute intracranial process. B12, folate, TSH, electrolytes, RPR, serum copper, ANA, anti-dsDNA, SS-A, SS-B, Smith, and RNP antibodies negative. Lupus anticoagulant, β2 glycoprotein, and anti-cardiolipin antibodies positive.  EEG unremarkable. Pelvic ultrasound negative. Genetic testing for Huntington’s negative. LP normal with exception of positive Coxsackie B1-B6 and A24 antibodies. After five-day course of IVIg, movements improved and she was discharged on no immunosuppression.

Five weeks later, patient returned to ED with worsening of choreoathetoid movements. Repeat head CT again negative for acute pathology. Repeated spinal was unremarkable. Patient received Solumedrol 1g for four days with significant improvement in symptoms, and discharged on Prednisone 60 mg daily with recommendation to follow-up with rheumatology and neurology.

On follow-up several months later, patient maintained on Prednisone 5 mg daily with no recurrence of choreoathetoid movements. 

While chorea is not the most commonly reported movement disorder in the context of autoimmune disease, it is often a delayed diagnosis, resulting in recurrent admissions and healthcare costs. Laboratory testing for autoimmune disorders should be included in the initial work-up of new-onset chorea to establish the diagnosis and properly treat as to prevent development of fulminant disease.

Authors/Disclosures
Amaris Alayon, MD
PRESENTER
Ms. Alayon has nothing to disclose.
Caleene R. Goodis, APRN (South Florida Neurology Associates, P.A.) Mrs. Goodis has nothing to disclose.
Marc H. Feinberg, MD (South Florida Neurology Ass.) Dr. Feinberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia. Dr. Feinberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Catalyst. Dr. Feinberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for eisai. Dr. Feinberg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Argenx. Dr. Feinberg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Feinberg has stock in Amarin.
Stuart N. Kieran, MD (South Florida Neurology Associates, PA) No disclosure on file
Elizabeth Wirkowski, MD (Wirkowski) Dr. Wirkowski has nothing to disclose.